Wichita Senior Care Guide

Cannabis Oil Cut Late-Stage Dementia Agitation in 87% of Patients — What Families Should Know Before Asking Their Doctor

The burden of late-stage agitation: Agitation — pacing, vocal outbursts, restlessness, and acute physical distress — affects roughly half of late-stage dementia patients and is one of the most distressing symptoms families deal with. More than a third of patients keep experiencing severe agitation despite standard prescriptions such as benzodiazepines, opioids, or antipsychotics, all of which carry significant risks of their own in older adults with dementia, including heavy sedation, falls, and FDA boxed warnings.

What the LiBBY trial actually was: LiBBY (Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol) was an NIH-funded Phase 2 randomized, double-blind, placebo-controlled trial of 120 participants, all hospice-eligible with advanced dementia and clinically significant agitation. Participants received a standardized oral combination of 2 mg THC / 100 mg CBD twice daily for 12 weeks (dissolved in digestible oil) or placebo; results were presented at AAIC 2026 (London).

What it found — and the honest safety picture: At week 12, 87.2% of treated patients were rated improved on clinician global impression vs. 23.6% on placebo; the benefit appeared fast (a 6.27-point greater reduction on the CMAI agitation scale at week 2, p=0.0004) and held through week 12 (p<0.0001). Stated plainly alongside that benefit, overall adverse-event rates were similar to placebo (46.7% vs. 42.4%), but serious adverse events were higher in the treatment arm (23.3% vs. 11.9%), and deaths were 13.1% vs. 5.1% with no specific cause pattern — numbers that must be read in the context of an end-of-life population, and that families deserve to see unspun.

What to ask the doctor:

• Is agitation like my parent’s the kind this trial studied? (LiBBY studied hospice-eligible, late-stage dementia patients with clinically significant agitation — not earlier-stage wandering or mild sundowning.)
• What have we already tried, and what did it cost them? Review non-drug comfort measures and current medications, including whether sedatives or antipsychotics are causing side effects without relieving distress.
• If we were interested, what would the legal and hospice-policy position be in our state and with our hospice? State laws, facility licensing rules, and hospice protocols vary widely.
• What interactions with current sedatives or opioids would we watch for? Oral THC and CBD can amplify sedation, dizziness, and drug levels when combined with benzodiazepines, opioids, or antipsychotics.
• What would we monitor, and when would we stop? Agree in advance on specific target symptoms, side-effect warning signs, and a clear stopping rule.

Essential caveats for families: This evidence comes from a single Phase 2 trial in a hospice-eligible end-of-life population only; the studied oral THC/CBD formulation is not a prescription option today; there is no long-term data beyond the 12-week trial; and the legal status of THC/CBD products varies by state. Commercial dispensary or over-the-counter CBD/THC products are not equivalent to a standardized clinical-trial formulation, and nothing in this section is a recommendation to obtain or use cannabis products.

Sources: Psychiatric Times: Oral Cannabinoid From MediPharm Shows Significant Reduction in Agitation in Alzheimer Disease and Dementia (2026-10-03); and The Educated Patient: A CBD/THC Combination Reduced Dementia Agitation in Nearly 9 in 10 Patients (2026-10-04).

Your Medicare Plan’s Star Rating May Be a Mirage This Year — 3 Things to Check Before Open Enrollment

The window: Medicare Open Enrollment runs October 15 – December 7, 2026, and changes take effect January 1, 2027. This is the one annual window most people have to switch Medicare Advantage or Part D prescription drug plans for 2027.

What actually changed in the ratings formula: CMS’s Contract Year 2027 final rule removed 11 Star Ratings measures — mostly administrative metrics such as call-center performance (including interpreter and TTY availability) and appeals handling — and reinstated the general reward factor in place of the Health Equity Index (HEI). Because fewer operational metrics can pull a composite score down, a plan can show a higher star rating this year without its care having improved at all. CMS’s own regulatory analysis projects roughly $18.5B ($18.56 billion) flowing to plan sponsors over 10 years from these formula and bonus-payment changes. Only one genuinely new clinical measure was added for the 2027 measurement year: depression screening and follow-up.

What families should do — read under the headline star: Check the underlying categories (drug coverage, care coordination, and member experience with the care itself), then verify the three things that actually determine whether a plan works for your parent in 2027:

1. Their medications are on the plan’s 2027 formulary at a tolerable tier — confirm every routine prescription, tier placement, and any prior-authorization or step-therapy rules (alongside the finalized 2027 Part D $700 maximum deductible and $2,400 annual out-of-pocket cap).
2. Their doctors and hospital are in network for 2027 — provider networks change yearly, so check each primary care physician, specialist, and hospital by name in the plan’s 2027 directory.
3. Their pharmacy is preferred in-network — copays at a standard in-network pharmacy can be substantially higher than at a preferred in-network pharmacy under the same plan.

Check stars last, not first. A high-starred plan that drops your parent’s specialist or moves a daily medication to a non-preferred tier will cost your family far more than a lower-starred plan that covers their actual doctors and prescriptions.

Watch for the marketing surge: Federal broker and agent marketing restrictions were loosened effective October 1, 2026, so families should expect a higher volume of calls, mailers, and ads this season — and should know that a sales call is not advice. For free, unbiased guidance with no sales commission, contact your local State Health Insurance Assistance Program (SHIP) counselor, and review our live Medicare Open Enrollment 2026 key dates explainer, 2027 plan-ending checklist, 2027 Medicare costs guide, and FAQ entry (“When is Medicare Open Enrollment for 2026?”) for the dates and plan-ending rules.

Sources & 2027 rule-change explainers: CMS Contract Year 2027 Medicare Advantage and Part D Final Rule Fact Sheet; Medicare Star Ratings 2027 Rule-Change Explainer (Avidon Health, updated 2026-10-03); and 2027 Star Ratings Measure-Set & Reward-Factor Analysis (RISE Health, updated 2026-10-03).